These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

625 related items for PubMed ID: 30655535

  • 21. BRN4 Is a Novel Driver of Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer and Is Selectively Released in Extracellular Vesicles with BRN2.
    Bhagirath D, Yang TL, Tabatabai ZL, Majid S, Dahiya R, Tanaka Y, Saini S.
    Clin Cancer Res; 2019 Nov 01; 25(21):6532-6545. PubMed ID: 31371344
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. PAX6 promotes neuroendocrine phenotypes of prostate cancer via enhancing MET/STAT5A-mediated chromatin accessibility.
    Jing N, Du X, Liang Y, Tao Z, Bao S, Xiao H, Dong B, Gao WQ, Fang YX.
    J Exp Clin Cancer Res; 2024 May 15; 43(1):144. PubMed ID: 38745318
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. FOXA1 inhibits prostate cancer neuroendocrine differentiation.
    Kim J, Jin H, Zhao JC, Yang YA, Li Y, Yang X, Dong X, Yu J.
    Oncogene; 2017 Jul 13; 36(28):4072-4080. PubMed ID: 28319070
    [Abstract] [Full Text] [Related]

  • 27. LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling.
    Luo J, Wang K, Yeh S, Sun Y, Liang L, Xiao Y, Xu W, Niu Y, Cheng L, Maity SN, Jiang R, Chang C.
    Nat Commun; 2019 Jun 12; 10(1):2571. PubMed ID: 31189930
    [Abstract] [Full Text] [Related]

  • 28. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L, Li H, Li Z, Li M, Tang Q, Wu C, Lu Z.
    Prostate; 2021 Jun 12; 81(9):508-520. PubMed ID: 33955576
    [Abstract] [Full Text] [Related]

  • 29. PROX1 drives neuroendocrine plasticity and liver metastases in prostate cancer.
    Liu C, Chen J, Cong Y, Chen K, Li H, He Q, Chen L, Song Y, Xing Y.
    Cancer Lett; 2024 Aug 10; 597():217068. PubMed ID: 38901665
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer.
    Ci X, Hao J, Dong X, Choi SY, Xue H, Wu R, Qu S, Gout PW, Zhang F, Haegert AM, Fazli L, Crea F, Ong CJ, Zoubeidi A, He HH, Gleave ME, Collins CC, Lin D, Wang Y.
    Cancer Res; 2018 May 15; 78(10):2691-2704. PubMed ID: 29487201
    [Abstract] [Full Text] [Related]

  • 32. Targeting RET Kinase in Neuroendocrine Prostate Cancer.
    VanDeusen HR, Ramroop JR, Morel KL, Bae SY, Sheahan AV, Sychev Z, Lau NA, Cheng LC, Tan VM, Li Z, Petersen A, Lee JK, Park JW, Yang R, Hwang JH, Coleman I, Witte ON, Morrissey C, Corey E, Nelson PS, Ellis L, Drake JM.
    Mol Cancer Res; 2020 Aug 15; 18(8):1176-1188. PubMed ID: 32461304
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
    Tsai HK, Lehrer J, Alshalalfa M, Erho N, Davicioni E, Lotan TL.
    BMC Cancer; 2017 Nov 13; 17(1):759. PubMed ID: 29132337
    [Abstract] [Full Text] [Related]

  • 35. Histone demethylase PHF8 drives neuroendocrine prostate cancer progression by epigenetically upregulating FOXA2.
    Liu Q, Pang J, Wang LA, Huang Z, Xu J, Yang X, Xie Q, Huang Y, Tang T, Tong D, Liu G, Wang L, Zhang D, Ma Q, Xiao H, Lan W, Qin J, Jiang J.
    J Pathol; 2021 Jan 13; 253(1):106-118. PubMed ID: 33009820
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
    Gururajan M, Cavassani KA, Sievert M, Duan P, Lichterman J, Huang JM, Smith B, You S, Nandana S, Chu GC, Mink S, Josson S, Liu C, Morello M, Jones LW, Kim J, Freeman MR, Bhowmick N, Zhau HE, Chung LW, Posadas EM.
    Oncotarget; 2015 Dec 29; 6(42):44072-83. PubMed ID: 26624980
    [Abstract] [Full Text] [Related]

  • 38. N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer.
    Dardenne E, Beltran H, Benelli M, Gayvert K, Berger A, Puca L, Cyrta J, Sboner A, Noorzad Z, MacDonald T, Cheung C, Yuen KS, Gao D, Chen Y, Eilers M, Mosquera JM, Robinson BD, Elemento O, Rubin MA, Demichelis F, Rickman DS.
    Cancer Cell; 2016 Oct 10; 30(4):563-577. PubMed ID: 27728805
    [Abstract] [Full Text] [Related]

  • 39. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
    Qi J, Nakayama K, Cardiff RD, Borowsky AD, Kaul K, Williams R, Krajewski S, Mercola D, Carpenter PM, Bowtell D, Ronai ZA.
    Cancer Cell; 2010 Jul 13; 18(1):23-38. PubMed ID: 20609350
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.